Caesarstone Ltd. (NASDAQ:CSTE – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.86 and traded as high as $5.04. Caesarstone shares last traded at $5.00, with a volume of 64,997 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut Caesarstone from a “buy” rating to a “hold” rating in a report on Monday, November 25th.
Check Out Our Latest Report on CSTE
Caesarstone Trading Down 1.4 %
Institutional Investors Weigh In On Caesarstone
A number of hedge funds have recently modified their holdings of CSTE. Empowered Funds LLC bought a new stake in Caesarstone during the 3rd quarter worth approximately $164,000. Bank of New York Mellon Corp bought a new stake in shares of Caesarstone during the second quarter worth $293,000. Rhumbline Advisers acquired a new stake in shares of Caesarstone during the second quarter worth $107,000. Acadian Asset Management LLC bought a new stake in Caesarstone in the 2nd quarter valued at $106,000. Finally, Gladius Capital Management LP bought a new stake in Caesarstone in the 2nd quarter valued at $28,000. Institutional investors and hedge funds own 33.70% of the company’s stock.
About Caesarstone
Caesarstone Ltd., together with its subsidiaries, designs, develops, manufactures, and markets engineered stone and other materials under the Caesarstone brand in the United States, Canada, Latin America, Australia, Asia, Europe, the Middle East and Africa, and Israel. The company’s engineered stone slabs are primarily used as indoor and outdoor kitchen countertops in the renovation and remodeling, and residential construction sectors.
Featured Articles
- Five stocks we like better than Caesarstone
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Effectively Use the MarketBeat Ratings Screener
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What Are the U.K. Market Holidays? How to Invest and Trade
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Caesarstone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caesarstone and related companies with MarketBeat.com's FREE daily email newsletter.